499 top medical experts on Membranoproliferative Glomerulonephritis across 54 countries and 26 U.S. states, including 375 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Membranoproliferative Glomerulonephritis: Chronic glomerulonephritis characterized histologically by proliferation of mesangial cells, increase in the mesangial extracellular matrix, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease systemic lupus erythematosus. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of mpgn.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Glomerulonephritis (2,699), Immune System Diseases (1,465).
  4. Clinical Trials ClinicalTrials.gov : at least 18 including 1 Active, 9 Completed, 3 Recruiting
  5. Synonyms: Mesangiocapillary Glomerulonephritis,  MPGN,  Mesangiocapillary Glomerulonephritis


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Sethi, Sanjeev   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Other (MD, 1985)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Disclosed payments from biomedical company (Novartis Pharmaceuticals Corporation) in 2021 for $10,000
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Kidney Glomerulus; Kidney; Paraproteinemias; Glomerulonephritis
    Categories: Immunology; Metabolism; Pathology; Analysis; Complications; Therapeutic Use
    C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. (2012)
    Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. (2012)

  2. Fervenza, Fernando C   Nephrology   ClinicalTrials.gov Google Publications
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota . Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $8,640, including $3,600 from  Otsuka Pharmaceutical Development & Commercialization, Inc.
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Kidney Glomerulus; Immunoglobulin G; Kidney; Paraproteinemias
    Categories: Immunology; Metabolism; Pathology; Therapeutic Use; Complications; Therapy
    C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. (2012)
    Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. (2011)

  3. Appel, Gerald B   Nephrology   ClinicalTrials.gov Google Publications
    Columbia University Medical Center, New York, NY. Electronic address: .
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 63 biomedical companies, totalling $93,797.31, including $40,352.33 from  GlaxoSmithKline, LLC.
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Antibodies, Monoclonal, Humanized; Glomerulonephritis; Kidney; Postoperative Complications
    Categories: Immunology; Pathology; Therapeutic Use; Drug Therapy; Analysis; Chemically Induced
    Eculizumab for dense deposit disease and C3 glomerulonephritis. (2012)
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. (2018)

  4. Bomback, Andrew S   Nephrology   Google Publications
    Department of Medicine, Division of Nephrology, Columbia University, New York, NY.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 10 biomedical companies, totalling $12,733.01, including $4,995 from  Otsuka Pharmaceutical Development & Commercialization, Inc.
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Antibodies, Monoclonal, Humanized; Complement System Proteins; Glomerulonephritis; Kidney
    Categories: Immunology; Drug Therapy; Therapeutic Use; Pathology; Genetics; Metabolism
    Eculizumab for dense deposit disease and C3 glomerulonephritis. (2012)
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. (2018)

  5. Nasr, Samih H   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Medical school: Other (MD, 1996)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Glomerulonephritis, Membranoproliferative; Kidney Glomerulus; Complement C3; Immunoglobulin G; Antibodies, Monoclonal; Autoimmune Diseases
    Categories: Immunology; Pathology; Complications; Metabolism; Analysis; Blood
    C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. (2012)
    Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. (2021)

  6. Nester, Carla M   Pediatric Nephrology   ClinicalTrials.gov Google Publications
    Molecular Otolaryngology and Renal Research Laboratories, University of Iowa, Iowa City, IA, United States. Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Disclosed payments in 2021 from 3 biomedical companies, totalling $5,000, including $4,850 from  Novartis Pharmaceuticals Corporation
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Autoantibodies; Complement C3 Nephritic Factor; Complement Factor B; Complement System Proteins
    Categories: Immunology; Metabolism; Therapeutic Use; Drug Therapy; Genetics; Classification
    Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. (2012)
    Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. (2011)

  7. Leung, Nelson   Nephrology   Google Publications
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Disclosed payments in 2021 from 2 biomedical companies, totalling $4,439.21, including $3,484 from  GENZYME CORPORATION
    Subjects: Glomerulonephritis, Membranoproliferative; Immunoglobulin G; Paraproteinemias; Antibodies, Monoclonal; Kidney; Acute Kidney Injury
    Categories: Immunology; Pathology; Complications; Metabolism; Diagnosis; Drug Therapy
    Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a nephrologist perspective. (2021)
    Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. (2011)

  8. Canetta, Pietro A   Nephrology   Google Publications
    Division of Nephrology, Columbia University Irving Medical Center, New York, New York .
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 3 biomedical companies, totalling $4,993.77, including $3,500 from  Travere Therapeutics, Inc.
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Kidney; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Complement C5
    Categories: Therapeutic Use; Immunology; Pathology; Drug Therapy; Analysis; Antagonists & Inhibitors
    Eculizumab for dense deposit disease and C3 glomerulonephritis. (2012)
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. (2018)

  9. Zand, Ladan   Nephrology  Google Publications
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 85/100
    Subjects: Glomerulonephritis, Membranoproliferative; Paraproteinemias; Complement C3; Adrenal Cortex Hormones; Antibodies, Monoclonal; Antineoplastic Agents
    Categories: Immunology; Complications; Drug Therapy; Therapeutic Use; Analysis; Metabolism
    C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. (2012)
    Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. (2014)

  10. Avasare, Rupali S   Nephrology   Google Publications
    Division of Nephrology, Department of Medicine, Oregon Health Science University, Portland, Oregon; .
    Physician  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 80.3/100
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Kidney; Postoperative Complications; Anti-Inflammatory Agents; Filgrastim
    Categories: Pathology; Therapeutic Use; Immunology; Chemically Induced; Adverse Effects; Analysis
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. (2018)
    Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. (2018)

  11. Cosio, Fernando G   Nephrology  Google Publications
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Glomerulonephritis, Membranoproliferative; Kidney Transplantation; Allografts; Antibodies, Monoclonal; Complement C3; Immunoglobulin G
    Categories: Pathology; Immunology; Surgery; Adverse Effects; Metabolism; Therapy
    Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. (2014)
    Recurrent membranoproliferative glomerulonephritis after kidney transplantation. (2010)

  12. Meyers, Kevin E C   Pediatric Nephrology  Google Publications
    Division of Nephrology, Department of Pediatrics, Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania.
    Physician  Case Reports 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $3,240, including $3,240 from  Alnylam Pharmaceuticals Inc.
    Subjects: Glomerulonephritis, Membranoproliferative; Kidney; Atypical Hemolytic Uremic Syndrome; Complement C3; Diacylglycerol Kinase; Streptococcal Infections
    Categories: Genetics; Analysis; Complications; Diagnosis; Immunology; Microbiology
    The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase (2017)
    Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). (2014)

  13. Alexander, Mariam P   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Top Hospital
    Physician  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Glomerulonephritis, Membranoproliferative; Kidney Glomerulus; Allografts; Antibodies, Monoclonal; Autoimmune Diseases; Complement C3
    Categories: Immunology; Pathology; Analysis; Etiology; Complications
    Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. (2015)
    Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. (2018)

  14. Markowitz, Glen S   Anatomic Pathology  Google Publications
    Department of Pathology and Cell Biology, Division of Renal Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Glomerulonephritis, Membranoproliferative; Complement C3; Antibodies, Monoclonal, Humanized; Glomerulonephritis; Kidney; Postoperative Complications
    Categories: Pathology; Immunology; Drug Therapy; Analysis; Chemically Induced; Therapeutic Use
    Eculizumab for dense deposit disease and C3 glomerulonephritis. (2012)
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. (2018)

  15. Radhakrishnan, Jai   Nephrology  Google Publications
    Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Disclosed payments in 2021 from 16 biomedical companies, totalling $31,087.5, including $9,200 from  GlaxoSmithKline, LLC.
    Subjects: Glomerulonephritis, Membranoproliferative; Kidney; Antibodies, Monoclonal, Humanized; Complement C3; Complement C5; Cryoglobulins
    Categories: Analysis; Pathology; Immunology; Antagonists & Inhibitors; Drug Therapy; Etiology
    Eculizumab for dense deposit disease and C3 glomerulonephritis. (2012)
    C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. (2018)

  16. Fogo, Agnes B   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN. Electronic address: .
    Physician  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 73.2/100
    Disclosed payments in 2021 from 10 biomedical companies, totalling $53,910, including $36,545 from  Novartis Pharmaceuticals Corporation
    Subjects: Glomerulonephritis, Membranoproliferative; Atlases as Topic; Cryoglobulinemia; Kidney; Nephrology; Periodicals as Topic
    Categories: Pathology; Therapeutic Use; Complications; Diagnosis; Drug Therapy
    AJKD Atlas of Renal Pathology: Fibronectin Glomerulopathy. (2017)
    Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. (2012)

  17. Nadasdy, Tibor   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Pathology, Division of Renal and Transplant Pathology, Ohio State University Wexner Medical Center, M018 Starling-Loving Hall, 320 W 10th Ave, Columbus, OH, 43210, USA. Top Hospital
    Physician  Case Reports 
    Medical school: Other (MD, 1981)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100
    Subjects: Glomerulonephritis, Membranoproliferative; Immunoglobulin G; Antibodies, Monoclonal; Immunosuppressive Agents; Kidney Glomerulus; Kidney Transplantation
    Categories: Immunology; Pathology; Analysis; Therapeutic Use
    Proliferative glomerulonephritis with monoclonal IgG deposits recurs or may develop de novo in kidney allografts. (2011)
    Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft. (2019)

  18. Cornell, Lynn D   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Top Hospital
    Physician  Highly Published  Case Reports 
    Medical school: University of Minnesota Medical School (MD, 2001)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Glomerulonephritis, Membranoproliferative; Kidney Glomerulus; Acute Kidney Injury; Allografts; Antibodies, Monoclonal; Autoantibodies
    Categories: Immunology; Complications; Pathology; Diagnosis; Analysis; Etiology
    Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. (2015)
    Dense deposit disease associated with monoclonal gammopathy of undetermined significance. (2010)

  19. Lusco, Mark A   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN.
    Physician 
    Medical school: University of Alabama School of Medicine (MD, 2001)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 73.2/100
    Subjects: Glomerulonephritis, Membranoproliferative; Atlases as Topic; Kidney; Nephrology; Periodicals as Topic
    Categories: Pathology; Diagnosis
    AJKD Atlas of Renal Pathology: Fibronectin Glomerulopathy. (2017)
    AJKD Atlas of Renal Pathology: Membranoproliferative Glomerulonephritis. (2015)

  20. Najafian, Behzad   Anatomic Pathology  Google Publications
    University of Washington, Department of Pathology, Seattle, WA 98195. Top Hospital
    Physician  Highly Published 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72/100
    Disclosed payments from biomedical company (SANOFI-AVENTIS U.S. LLC) in 2021 for $2,925
    Subjects: Glomerulonephritis, Membranoproliferative; Atlases as Topic; Glomerulonephritis, IGA; Diabetic Nephropathies; Eosinophilia; Glomerulonephritis, Membranous
    Categories: Pathology; Diagnosis; Immunology
    Interstitial eosinophilic aggregates in diabetic nephropathy: allergy or not? (2015)
    AJKD Atlas of Renal Pathology: Fibronectin Glomerulopathy. (2017)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);